Unknown

Dataset Information

0

Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis.


ABSTRACT:

Importance

Amyloid-β positron emission tomography (PET) imaging allows in vivo detection of fibrillar plaques, a core neuropathological feature of Alzheimer disease (AD). Its diagnostic utility is still unclear because amyloid plaques also occur in patients with non-AD dementia.

Objective

To use individual participant data meta-analysis to estimate the prevalence of amyloid positivity on PET in a wide variety of dementia syndromes.

Data sources

The MEDLINE and Web of Science databases were searched from January 2004 to April 2015 for amyloid PET studies.

Study selection

Case reports and studies on neurological or psychiatric diseases other than dementia were excluded. Corresponding authors of eligible cohorts were invited to provide individual participant data.

Data extraction and synthesis

Data were provided for 1359 participants with clinically diagnosed AD and 538 participants with non-AD dementia. The reference groups were 1849 healthy control participants (based on amyloid PET) and an independent sample of 1369 AD participants (based on autopsy).

Main outcomes and measures

Estimated prevalence of positive amyloid PET scans according to diagnosis, age, and apolipoprotein E (APOE) ε4 status, using the generalized estimating equations method.

Results

The likelihood of amyloid positivity was associated with age and APOE ε4 status. In AD dementia, the prevalence of amyloid positivity decreased from age 50 to 90 years in APOE ε4 noncarriers (86% [95% CI, 73%-94%] at 50 years to 68% [95% CI, 57%-77%] at 90 years; n = 377) and to a lesser degree in APOE ε4 carriers (97% [95% CI, 92%-99%] at 50 years to 90% [95% CI, 83%-94%] at 90 years; n = 593; P < .01). Similar associations of age and APOE ε4 with amyloid positivity were observed in participants with AD dementia at autopsy. In most non-AD dementias, amyloid positivity increased with both age (from 60 to 80 years) and APOE ε4 carriership (dementia with Lewy bodies: carriers [n = 16], 63% [95% CI, 48%-80%] at 60 years to 83% [95% CI, 67%-92%] at 80 years; noncarriers [n = 18], 29% [95% CI, 15%-50%] at 60 years to 54% [95% CI, 30%-77%] at 80 years; frontotemporal dementia: carriers [n = 48], 19% [95% CI, 12%-28%] at 60 years to 43% [95% CI, 35%-50%] at 80 years; noncarriers [n = 160], 5% [95% CI, 3%-8%] at 60 years to 14% [95% CI, 11%-18%] at 80 years; vascular dementia: carriers [n = 30], 25% [95% CI, 9%-52%] at 60 years to 64% [95% CI, 49%-77%] at 80 years; noncarriers [n = 77], 7% [95% CI, 3%-18%] at 60 years to 29% [95% CI, 17%-43%] at 80 years.

Conclusions and relevance

Among participants with dementia, the prevalence of amyloid positivity was associated with clinical diagnosis, age, and APOE genotype. These findings indicate the potential clinical utility of amyloid imaging for differential diagnosis in early-onset dementia and to support the clinical diagnosis of participants with AD dementia and noncarrier APOE ε4 status who are older than 70 years.

SUBMITTER: Ossenkoppele R 

PROVIDER: S-EPMC4517678 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis.

Ossenkoppele Rik R   Jansen Willemijn J WJ   Rabinovici Gil D GD   Knol Dirk L DL   van der Flier Wiesje M WM   van Berckel Bart N M BN   Scheltens Philip P   Visser Pieter Jelle PJ   Verfaillie Sander C J SC   Zwan Marissa D MD   Adriaanse Sofie M SM   Lammertsma Adriaan A AA   Barkhof Frederik F   Jagust William J WJ   Miller Bruce L BL   Rosen Howard J HJ   Landau Susan M SM   Villemagne Victor L VL   Rowe Christopher C CC   Lee Dong Y DY   Na Duk L DL   Seo Sang W SW   Sarazin Marie M   Roe Catherine M CM   Sabri Osama O   Barthel Henryk H   Koglin Norman N   Hodges John J   Leyton Cristian E CE   Vandenberghe Rik R   van Laere Koen K   Drzezga Alexander A   Forster Stefan S   Grimmer Timo T   Sánchez-Juan Pascual P   Carril Jose M JM   Mok Vincent V   Camus Vincent V   Klunk William E WE   Cohen Ann D AD   Meyer Philipp T PT   Hellwig Sabine S   Newberg Andrew A   Frederiksen Kristian S KS   Fleisher Adam S AS   Mintun Mark A MA   Wolk David A DA   Nordberg Agneta A   Rinne Juha O JO   Chételat Gaël G   Lleo Alberto A   Blesa Rafael R   Fortea Juan J   Madsen Karine K   Rodrigue Karen M KM   Brooks David J DJ  

JAMA 20150501 19


<h4>Importance</h4>Amyloid-β positron emission tomography (PET) imaging allows in vivo detection of fibrillar plaques, a core neuropathological feature of Alzheimer disease (AD). Its diagnostic utility is still unclear because amyloid plaques also occur in patients with non-AD dementia.<h4>Objective</h4>To use individual participant data meta-analysis to estimate the prevalence of amyloid positivity on PET in a wide variety of dementia syndromes.<h4>Data sources</h4>The MEDLINE and Web of Scienc  ...[more]

Similar Datasets

| S-EPMC4486209 | biostudies-literature
| S-EPMC9531087 | biostudies-literature
| S-EPMC3821718 | biostudies-literature
| S-EPMC6142936 | biostudies-literature
| S-EPMC8111744 | biostudies-literature
| S-EPMC8819863 | biostudies-literature
| S-EPMC11350128 | biostudies-literature
| S-EPMC5473545 | biostudies-literature
| S-EPMC11567875 | biostudies-literature
| S-EPMC7608617 | biostudies-literature